-->

Company Registry

QrumPharma Inc
Profile last edited on: 10/2/2019

Inhaled therapies for severe and orphan lung diseases
Year Founded
2014
First SBIR Year
2018
Latest SBIR Award
2018
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

215 Decatur Street
Doylestown, PA 18901
   (919) 247-7696
   info@qrumpharma.com
   www.qrumpharma.com
Multiple Locations:   
Congressional District:   01
County:   Bucks

Public Profile

Qrumpharma is structured around developing first-in-class therapeutics for the treatment of severe chronic and recurrent pulmonary infections and diseases, such as those caused by Nontuberculous Mycobacteria (NTM) and Tuberculosis. The firm's name - Qrumpharma - is derived from quorum sensing, in which colonies of bacteria can work together to be more successful than an individual. The team assembled by Qrumpharma includes experienced entrepreneurs working together to develop novel products and bring them to the market place.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Thomas Hofmann -- CEO and Founder

  Brandon Banaschewski -- Senior Scientist

  Med Sebastian Canisius -- Consultant Clinical Development Respiratory/Infectious Diseases

  Stefan Ufer --

SBIR firms in the news

There are no news available.